MedPath

Liothyronine

Generic Name
Liothyronine
Brand Names
Cytomel, Np Thyroid
Drug Type
Small Molecule
Chemical Formula
C15H12I3NO4
CAS Number
6893-02-3
Unique Ingredient Identifier
06LU7C9H1V
Background

Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.

Indication

Liothyronine is officially approved for the following indications:

In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels.

The lack of liothyronine can be presented as a pale and puffy face, coarse, brittle hair, dry skin, croaky voice and constipation as well as irregular periods, drowsiness, and lethargy.

Liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis.

Associated Conditions
Autonomy of thyroid gland, Hyperthyroidism, Hypothyroidism, Myxedema coma, Thyroid Cancer, Euthyroid Goitre, Myxedema pre-coma
Associated Therapies
Supplemental or replacement therapy
Clinical Trials
Related News

Thyroid Hormone for Thyroid Cancer

Not yet recruiting
Conditions
Differentiated Thyroid Cancer
Thyroid Cancer
Levothyroxine
Liothyronine
Thyroid Hormones
Interventions
First Posted Date
2024-10-18
Last Posted Date
2024-10-18
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
40
Registration Number
NCT06647602
Locations
🇳🇱

University Medical Center Groningen (UMCG), Groningen, Netherlands

🇳🇱

Radboud University Nijmegen, Nijmegen, Netherlands

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

Phase 1
Recruiting
Conditions
Heart Failure
Interventions
Other: Control Group
First Posted Date
2022-05-20
Last Posted Date
2024-08-27
Lead Sponsor
Emory University
Target Recruit Count
20
Registration Number
NCT05384847
Locations
🇺🇸

Emory University Hospital Clinical Research Network, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital (EUH), Atlanta, Georgia, United States

Thyroid Hormone Supplementation in Patients With Septic Shock

Phase 2
Completed
Conditions
Septic Shock
Euthyroid Sick Syndromes
Interventions
First Posted Date
2022-03-08
Last Posted Date
2023-09-28
Lead Sponsor
Cantonal Hospital Zenica
Target Recruit Count
108
Registration Number
NCT05270798
Locations
🇧🇦

Cantonal Hospital, Zenica, Bosnia and Herzegovina

Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma

Early Phase 1
Withdrawn
Conditions
Recurrent Gliosarcoma
Recurrent Glioblastoma
Interventions
First Posted Date
2021-08-24
Last Posted Date
2022-12-02
Lead Sponsor
Emory University
Registration Number
NCT05017610

Energy Metabolism in Thyroidectomized Patients

Phase 2
Completed
Conditions
Thyroid Goiter
Hypothyroidism
Thyroid Cancer
Interventions
Drug: Placebo
First Posted Date
2021-03-04
Last Posted Date
2024-06-14
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
13
Registration Number
NCT04782856
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Phase 2
Active, not recruiting
Conditions
Recurrent Medulloblastoma
Recurrent Ependymoma
Interventions
Drug: SSKI
Drug: anti-emetics
Drug: Antipyretic
Drug: Antihistamine
First Posted Date
2021-02-08
Last Posted Date
2024-08-06
Lead Sponsor
Pediatric Brain Tumor Consortium
Target Recruit Count
62
Registration Number
NCT04743661
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

Phase 2
Not yet recruiting
Conditions
ARDS
Covid19
SARS-CoV Infection
ARDS, Human
Interventions
Other: Placebo Therapy
First Posted Date
2021-01-26
Last Posted Date
2025-02-17
Lead Sponsor
University of Minnesota
Target Recruit Count
250
Registration Number
NCT04725110
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection

Phase 2
Terminated
Conditions
Pulmonary Infection
Covid-19
Interventions
Drug: Placebo
First Posted Date
2020-04-16
Last Posted Date
2021-09-23
Lead Sponsor
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Target Recruit Count
5
Registration Number
NCT04348513
Locations
🇬🇷

Attikon University General Hospital, Haidari/Athens, Greece

Treatment of ARDS With Instilled T3

Phase 2
Recruiting
Conditions
ARDS, Human
Lung, Wet
Thyroid
Pulmonary Edema
Lung Inflammation
Interventions
Other: Non-intervention
First Posted Date
2019-10-04
Last Posted Date
2024-10-26
Lead Sponsor
University of Minnesota
Target Recruit Count
68
Registration Number
NCT04115514
Locations
🇺🇸

M Health Fairview Southdale Hospital, Edina, Minnesota, United States

🇺🇸

East Bank Hospital - M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States

Developing Oral LT3 Therapy for Heart Failure - HFrEF

Phase 1
Completed
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF)
Low T3 Syndrome
Interventions
Other: Placebo
First Posted Date
2019-10-02
Last Posted Date
2024-12-24
Lead Sponsor
University of Pennsylvania
Target Recruit Count
28
Registration Number
NCT04112316
Locations
🇺🇸

PennMedicine, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy